Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers
Cancer · 2025-06 · 131 (11)
DOI: 10.1002/cncr.35910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 28.05.2025. Verfasst von Kerollos Nashat Wanis und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Sentinel Lymph Node Biopsy, Clinical Decision-Making. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Background
Selective omission of sentinel lymph node biopsy (SLNB) in patients with early breast cancer limits surgical morbidity. Adoption of this strategy relies on multidisciplinary consensus. Understanding how SLNB omission influences guideline‐based adjuvant treatment decisions, and the proportion of patients impacted, can help guide decision‐making. Patients and methods Data from the National Cancer Database (2018–2020) was used to estimate the proportions of patients with cT1N0 hormone receptor–positive breast cancer for whom adjuvant chemotherapy, CDK4/6 inhibitor therapy, and regional nodal irradiation decisions would be impacted by the absence of lymph node pathology if national treatment guidelines were followed. Because OncotypeDX score is essential to adjuvant decision‐making when SLNB is omitted, inverse probability weighting was used to estimate the proportions of interest had all individuals undergone OncotypeDX testing.
Results
There were 119,312 included patients, with an average age of 63 years, 96,454 (80.8%) having invasive ductal histology, and 52,222 (43.8%) having cT1c tumors. The number of patients with SLNB positivity was 13,211 (11.1%). Among postmenopausal women, 7.9% (95% CI, 7.7–8.1) would have had at least one adjuvant decision impacted by the absence of lymph node pathology. For premenopausal women, the affected proportion was 13.7% (95% CI, 13.0–14.7). When ribociclib decision‐making was not considered, these estimates were 2.5% for postmenopausal women and 12.6% for premenopausal women.
Conclusions
SLNB omission has a small – but not negligible – influence on adjuvant decision making in postmenopausal women, whereas a larger proportion of premenopausal women would be impacted. The reported estimates may inform multidisciplinary decision‐making related to SLNB omission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Jennifer Keating Litton, Nina Tamirisa, Isabelle Bedrosian, Susie X Sun, Abigail S Caudle, Funda Meric-Bernstam, Taiwo Adesoye
Förderung
- NCI NIH HHS
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Wanis, K. N., Mitchell, M. P., Giordano, S. H., Litton, J. K., Shaitelman, S. F., Tamirisa, N., Bedrosian, I., Dong, W., Shen, Y., Hunt, K. K., Singh, P., Sun, S. X., Caudle, A. S., Kuerer, H. M., Meric-Bernstam, F., Hwang, R. F., & Adesoye, T. (2025). Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers. Cancer, 131(11). https://doi.org/10.1002/cncr.35910
Vancouver
Wanis KN, Mitchell MP, Giordano SH, Litton JK, Shaitelman SF, Tamirisa N, et al. Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers. Cancer. 2025;131(11). doi:10.1002/cncr.35910
BibTeX
@article{Wanis2025,
author = {Wanis, Kerollos Nashat and Mitchell, Melissa P and Giordano, Sharon H and Litton, Jennifer Keating and Shaitelman, Simona F and Tamirisa, Nina and Bedrosian, Isabelle and Dong, Wenli and Shen, Yu and Hunt, Kelly K and Singh, Puneet and Sun, Susie X and Caudle, Abigail S and Kuerer, Henry M and Meric-Bernstam, Funda and Hwang, Rosa F and Adesoye, Taiwo},
title = {Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers},
journal = {Cancer},
year = {2025},
volume = {131},
number = {11},
doi = {10.1002/cncr.35910}
}
EUVIMED